

List of Figures

Figure 1.1: Pathophysiological factors involved in diabetes comorbid depression.....	8
Figure 1.2: Oxidative mechanism for diabetes comorbid depression.....	10
Figure 1.3: HPA axis alteration in diabetes comorbid depression (Benson and Stuart, 1993).....	13
Figure 1.4: Neuronal damage mechanism for diabetes comorbid depression	16
Figure 1.5: Mitochondrial dysfunction mechanism involved in the induction of diabetes comorbid depression	20
Figure 1.6: Inflammatory mechanism for diabetes comorbid depression.....	23
Figure 1.7: Epigenetic modification for induction of diabetes comorbid depression....	25
Figure 1.8: Structure of metformin	31
Figure 1.9: Synthesis of metformin	31
Figure 1.10: ADME of metformin	33
Figure 1.11: Mechanism of action of metformin in diabetes.....	35
Figure 2.1: Schematic representation of experimental protocol.	52
Figure 2.2: Ascorbic acid against comorbid depression	58
Figure 2.3: Ascorbic acid against hyperglycemia and hypoinsulinemia	59
Figure 2.4: Ascorbic acid against oxidative stress.....	61
Figure 2.5: Ascorbic acid against inflammation	62
Figure 3.1: Schematic representation of experimental protocol.	73
Figure 3.2: Metformin against comorbid depression.....	76
Figure 3.3: Metformin against hyperglycemia and hypoinsulinemia	77
Figure 3.4: Metformin against reduction in monoamine levels.....	78
Figure 3.5: Metformin against inflammatory cytokines in prefrontal cortex	79

Figure 3.6: Metformin against oxidative stress markers in prefrontal cortex.....	80
Figure 4.1: Schematic representation of experimental protocol.	90
Figure 4.2: Effects of combination therapy on comorbid depression.....	95
Figure 4.3: Effects of combination therapy on hyperglycemia and hypoinsulinemia ...	96
Figure 4.4: Effects of combination therapy on brain monoamine levels.....	98
Figure 4.5: Effects of combination therapy on oxidative stress.....	99
Figure 4.6: Effects of combination therapy on proinflammatory cytokine levels	101
Figure 5.1: Schematic representation of experimental protocol.	114
Figure 5.2: Confirmation of activity against depressive-like markers.....	118
Figure 5.3: Effect on mitochondrial membrane potential and ROS	119
Figure 5.4: Effect on caspase -9 and caspase-3 expression in the prefrontal cortex ...	120
Figure 5.5: Effect on BDNF expression in the prefrontal cortex.....	121
Figure 5.6: Effect on NF- κ B expression in the prefrontal cortex	122